Loading clinical trials...
Loading clinical trials...
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation
Conditions
Interventions
Mavrilimumab
Placebos
Locations
1
United States
Virginia Commonwealth University
Richmond, Virginia, United States
Start Date
September 2, 2020
Primary Completion Date
November 30, 2020
Completion Date
November 30, 2020
Last Updated
August 11, 2021
NCT07221162
NCT06082518
NCT06631287
NCT06679140
NCT07409727
NCT06417762
Lead Sponsor
Virginia Commonwealth University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions